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Abstract
Background: The aim of the current study was to examine impacts of the Finnish breast cancer
(BC) screening programme on the population-based incidence and mortality rates. The programme
has been historically targeted to a rather narrow age band, mainly women of ages 50–59 years.
Methods: The study was based on the information on breast cancer during 1971–2003 from the
files of the Finnish Cancer Registry. Incidence, cause-specific mortality as well as incidence-based
(refined) mortality from BC were analysed with Poisson regression. Age-specific incidence and
routine cause-specific mortality were estimated for the most recent five-year period available;
incidence-based mortality, respectively, for the whole steady state of the programme, 1992–2003.
Results: There was excess BC incidence with actual screening ages; incidence in ages 50–69 was
increased 8% (95 CI 2.9–13.4). There was an increasing temporal tendency in the incidence of
localised BC; and, respectively, a decrease in that of non-localised BC. The latter was most
consistent in age groups where screening had been on-going several years or eventually after the
last screen. The refined mortality rate from BC diagnosed in ages 50–69 was decreased with -11.1%
(95% CI -19.4, -2.1).
Conclusions: The current study demonstrates that BC screening in Finland is effective in reducing
mortality rates from breast cancers, even though the impact on the population level is smaller than
expected based on the results from randomised trials among women screened in age 50 to 69. This
may be explained by the rather young age group targeted in our country. Consideration whether
to targeted screening up to age 69 is warranted.
Background
Impact of mammography screening in decreasing breast
cancer (BC) mortality has been shown among women
invited in ages 50–69 in several randomised trials [1].
There is growing evidence from cohort follow-up studies
that the service screening programmes implemented in
the late 1980s or early 1990s affect breast cancer mortality
among invited with at least a similar degree than the ran-
domised trials [2-6]. Studies using dynamic materials [7-
9] or modelling historical screening coverage [10,11] have
also demonstrated effectiveness of organised screening.
On the other hand, there are proposals that screening has
not clearly affected population breast cancer mortality
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rates [12,13] or, breast cancer or overall mortality is not
affected in general [14,15].
There are several biases in the dynamic population-based
studies. Death from breast cancer occurs often several
years after the diagnosis; studies based on routine deaths
records may suffer from misclassification of the screening
status [2,7,12]. This can be corrected if incidence-based
mortality is used. Another source of bias in the early trend
studies is that national screening programmes have been
introduced gradually, and the screening coverage in the
targeted groups had become complete only after several
years of implementation.
The aim of the current study was to examine impacts of
the breast cancer screening programme in Finland on the
population-based incidence and mortality rates. Finland
makes an exceptional setting for the study, because the
programme has been targeted historically to a rather nar-
row age band mainly among women of ages 50–59 years.
Methods
The study was based on the information on breast cancer
(ICD-10 code C50) from the files of the Finnish Cancer
Registry. The women diagnosed with a new (incident) pri-
mary breast cancer (N = 74,175), or died from breast can-
cer (N = 22,799), in 1971–2003 were included. Analysis
was restricted to invasive breast cancers. Following tar-
geted age groups in screening, ages 40–69 were included
in the analysis of incidence data; follow-up of subsequent
deaths from breast cancer was extended up to age 79. The
incident cases were classified into two groups by stage of
the disease, localised and non-localised at diagnosis,
based on information mainly on the lymph node status as
available in the cancer registration. Among 9.4% of the BC
cases the stage information was not available at the cancer
registry. The proportion cases with stage unknown was
13% in 2003 and thus stage-specific information was con-
sidered adequate for the analyses up to the year 2002.
In order to assess historical coverage of screening,
national data on the invitations were collected from the
records of the Mass Screening Registry – a subunit of the
Finnish Cancer Registry. Coverage of the screening regis-
tration is variable during the 15 years' period of routine
BC screening: in 1987–1990 the average coverage of regis-
tration of invitations is 83% (N = 358,200/431,300)
whereas from 1991 onwards the estimated annual regis-
tration coverage is > 95% (1,257,000/1,259,200; the esti-
mated average registration coverage 99.8%). These
estimates are derived from comparisons of the yearly reg-
istered invitations with an external documentation on the
invitations, maintained by the Radiological Society of Fin-
land [16].
If a municipality or a screening centre had not registered
their invitations, we requested from the municipality
health authorities or screening centres mailed informa-
tion on invited age groups, by birth cohort and invita-
tional year, and estimated thereafter the biannual
coverage of invitations by combining numbers of invited
with the respective population data. We obtained mailed
information on screening invitations during 1987–1990
for 140 municipalities for which there were registered
invitational data available only from 1991 onwards. Dur-
ing the overall study period the number of municipalities
changed from 461 (1987, 1988) to 446 (2002); annual
invitational data became available in total for 410 (89%)
of them.
For incidence-based, i.e., refined mortality, individual
patient data were studied. Only those deaths were
included, where the diagnosis of breast cancer took place
in the given calendar period and age group. For the
refined mortality, the age was defined as the age at diag-
nosis of the corresponding incident case. Deaths from
breast cancer were included and stratified by the 5-year
calendar period, birth-cohort, and age at diagnosis. In
these data, breast cancer deaths taking place at an older
age than 79 years were excluded. The length of follow-up
after diagnosis was made symmetric between the groups
on age and period: Deaths in 1972–1983 among those
diagnosed in 1972–76 in ages 40 and 69, deaths in
1977–88 among those diagnosed in 1977–81 in ages
40–69, and so on, until deaths in 1992–2003 among
those diagnosed in 1992–1996. There was thus a 5-year
long period for incidence and a 12-year long period for
mortality in each time window. Incident cases from the
calendar period 1992–1996 were the most recent ones
included in this incidence-based analysis. This restriction
was done to obtain comparability of information over the
decades, and to obtain also as long follow-up time as pos-
sible.
Annual population denominators were used by 1-year age
group for estimating screening coverage, as well as in esti-
mating refined mortality follow-up; and by 5-year age
group by calendar year for breast cancer incidence and
routine mortality rates.
Coverage estimates of screening
Invitational coverage was defined as the number of
women invited at least once within the recommended
screening interval (a two-year period) per population size.
The actual invitational coverage increased gradually dur-
ing the first five years of the programme, 1987–1991; i.e.,
during the pseudo-randomised implementation phase
(Figure 1). The actual coverage proportions were con-
verted to estimates describing invitation (yes/no) ever in
lifetime. Estimated coverage of 'ever' invited was approxi-BMC Public Health 2008, 8:38 http://www.biomedcentral.com/1471-2458/8/38
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mated within ages 50–64 at 10%–89% during
1987–1991, and 100% since 1992. In ages 65–69, life-
time coverage increased over 10% since 1992 and up to
100% since 1997; mainly while ageing of the invited
group.
Statistical analyses
The incidence of and mortality from breast cancer as well
as the incidence-based mortality were analysed with Pois-
son regression. To adjust for the fluctuating changes in the
incidence and mortality with age and cohort, the inci-
dence and mortality were modelled as functions of
numerical calendar year and polynomials of numerical
age at 5-year age groups and synthetic birth cohort [17].
The orders of polynomials i.e., the forms of marginal age
and cohort curves were searched for overall incidence,
localised and non-localised incidence, and mortality sep-
arately using the data of calendar period 1953–1970. The
decision of the chosen degrees of polynomials was based
on the likelihood ratio statistic and descriptive evaluation.
In the estimation of overall incidence, 10th order polyno-
mial of age and 4th order polynomial of cohort were
needed, in localised and non-localised incidence the cor-
responding orders of age were 10 and 6, and of cohort 8
and 2, respectively, and in mortality the orders of polyno-
mials were 5 for both age and cohort. In the analysis of
incidence-based mortality, the orders of polynomials for
age at diagnosis and cohort were both 3, and each year in
the follow-up between the diagnosis and death was
included as a level of categorical variable.
In the statistical analyses we paid emphasis on the steady
state of the programme with a high actual screening cov-
erage among women in the main target ages (particularly,
ages 50–59). We included an indicator for the period from
1992 onwards – with the exclusion of years 1987–91 –
indicating the steady state of the screening programme.
During the steady state, prevalence screens took place
mainly at the onset at age 50. In the first descriptive phase,
observation during the recent screening period
1998–2002 was contrasted with expectation without
screening as drawn from modelling information prior to
the screening era (years 1971–1986) within each age
group. Because of the symmetry requirements in the data
input when studying incidence-based mortality (see
above), this expectation could not be estimated for the
completely same period of time and these results are
shown separately. In the second phase, the effect of
screening was studied for the screened age groups only
(with the estimated coverage at least 90%). For example,
the age group 60–64 years consisted of screened birth-year
cohorts after 1992, and the groups 65–69 years since
1997. In order to estimate screening effects, parallel devel-
opments among screened and non-screened were
assumed. Non-screened group consisted here of women
in ages 40–49 -years; and ages 65–69 years up to the end
of 1991. Note that even the observed incidence and mor-
tality rates shown below in the Tables are based on mod-
els.
Ethical consideration
Information on the breast cancer incidence and mortality,
as well as on the population numbers and screening indi-
ces were based on tabular statistical data only; according
to the current legislature, no approval from the ethical
committee was required.
Results
Table 1 shows age-specific BC incidence and mortality
rates observed in 1998–2002; corresponding estimates
without screening as extrapolated from mortality experi-
ence in these same age groups from time before national
implementation of screening; excess relative risk esti-
mates; and woman-years at risk. In addition, Figures 2 and
3 illustrate the overall developments of BC incidence and
routine mortality trends by calendar year and 5-year age
group among women in ages 40–69; as well as the values
obtained by fitting the models.
There was excess BC incidence with actual screening ages
(18% and 11% in ages in age 50–54 and 55–59 years,
Table 1). Among all age groups studied, there was an
increasing tendency of localised breast cancers, particu-
larly pronounced in screening target ages; and, respec-
tively, a decreasing trend in incidence of non-localised
breast cancers. The decrease in the incidence of non-local-
ised breast cancers was most consistent in ages 55 to 69
years, i.e. in late screening or up to five years after the last
screen.
Estimated biannual coverage of invitations in the national  breast cancer screening programme in Finland in 1982–2003,  by age Figure 1
Estimated biannual coverage of invitations in the national 
breast cancer screening programme in Finland in 1982–2003, 
by age.
1980 1982 1984 1986 1988 1990 1992 1994 1996 1998 2000 2002 2004
0
20
40
60
80
100
 
 
4
0
-
4
4
 
 
4
5
-
4
9
 
 
5
0
-
5
4
 
 
5
5
-
5
9
 
 
6
0
-
6
4
 
 
6
5
-
6
9
 
 
7
0
-
7
4
 
 
7
5
-
7
9
Y
e
a
rBMC Public Health 2008, 8:38 http://www.biomedcentral.com/1471-2458/8/38
Page 4 of 10
(page number not for citation purposes)
Age-specific routine breast cancer mortality rate had
increased up to mid-1990s particularly in ages younger
than targeted by the national screening programme (ages
40–44, and 45–49 years; Table 1). We observed a consist-
ent decreasing trend in the mortality rate since the mid-
1990s among all studied age groups, however (Figure 3).
In general, the death rates in ever-screened age groups (50
to 69, age at death) had increased less than among non-
screened or remained stable (Table 1).
Incidence-based mortality rates from breast cancers diag-
nosed in ages 40–49 showed an increase of 28%–34%. In
screening ages (50 to 69), the corresponding point esti-
mates showed slightly smaller increase or a decreasing
tendency (Table 2). The decrease was largest in deaths
from BC cases which had been diagnosed in ages 55–59
and 60–64. Specific to the age groups, the incidence-based
mortality result was statistically significant only among
women of ages 45–49.
Observed and fitted breast cancer incidence rates by age group Figure 2
Observed and fitted breast cancer incidence rates by age group. The first five years since the implementation of the national 
programme have been excluded from the fitted rates.
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Table 3 summarises the tentative screening effects,
obtained from comparisons of trends between screened
and non-screening age groups. The overall BC incidence
was in excess of 8.0%; particularly the incidence of local-
ised BCs was in excess (22.5%). Incidence of non-local-
ised breast cancers at diagnosis was 9.0% lower than the
expectation if absence of screening. Routine BC mortality
in all the screened ages combined (age at death) had
decreased with -5.6% as compared with expectation with-
out screening. Change in refined BC mortality was -11.1%
(95% CI -19.4, -2.1%), respectively. Among women
screened most intensively (50–64) the corresponding esti-
mates by 5-year age groups were -3.1 %, -14.7% and -
17.1%, respectively.
Discussion
Two phases of analysis were constructed. The first,
descriptive phase (Tables 1 and 2) gave an overall picture
of the situation, whereas the second, more analytic phase
(Table 3), targeted directly at estimation of the effects of
Observed and fitted breast cancer mortality rates by age group at death Figure 3
Observed and fitted breast cancer mortality rates by age group at death. The first five years since the implementation of the 
national programme have been excluded from the fitted rates.
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the screening programme. In association with the steadily
running breast cancer screening service, we observed a
slight increase in the overall breast cancer incidence, and
a decrease in the incidence of non-localised breast can-
cers. Decrease in the incidence of non-localised breast
cancers may be considered an indicator predicting reduc-
tions in the mortality rate. A small even though statisti-
cally non-significant decrease was documented in the
breast cancer mortality among the invited age groups. The
effect of screening as obtained from incidence-based mor-
tality analysis varied at -3.1 – -17.1% in the most inten-
sively screened age groups. Despite the higher than
predicted mortality, we observed a consistent recent
decrease in breast cancer mortality since the mid-1990s in
all the studied age groups 40–69.
The invitational coverage of the screening programme was
close to 100% in the major targeted ages of the organised
screening programme, 50–59 years of age; among non-
targeted only a very low coverage was observed. We made
efforts to assess coverage of the registered invitations
using external information. Attendance (compliance)
rates in the programme have been very high; during
1991–1999 at 89% at first screen and at 92% at subse-
quent screens as reported from 10 centres constituting
55–60% of the screenings of the whole national pro-
gramme [18]. The Finnish Radiological Society [16]
reported an average compliance rate of 89% among all the
centres in 1987–1997, respectively.
In the implementation period there was a randomised
screening design, affecting the population-based cover-
age. After 1991 (after the randomisation period) some
Table 2: Observed and expected incidence-based mortality (/100) in 1992–2002 from breast cancers diagnosed in 1992–96 and the 
modelled changes in the incidence-based mortality from breast cancers diagnosed in the three five-year periods during 1972–1986 to 
1992–1996, by age at diagnosis.
Age group at diagnosis (years)
40–44 45–49 50–54 55–59 60–64 65–69 40–69 50–69
Observed 0.005 0.008 0.011 0.009 0.011 0.013 0.009 0.011
Expected 1 0.004 0.006 0.010 0.010 0.012 0.012 0.009 0.011
Excess relative risk (in %)1 34 28 * 11 -7 -11 11 4 -3
1 (Observed – expected)/expected * Significant at 0.05 level
Table 1: Woman-years at risk, and observed and expected incidence and mortality rates (/100) of breast cancer in Finland in 
1998–2002 by age group. The expected rates are based on an extrapolation of models fitted in the data during 1971–1986 (before 
screening era).
Age group (years)
40–44 45–49 50–54 55–59 60–64 65–69 40–69 50–69
Woman-years at risk 943,300 992,500 1,034,400 788,500 680,900 614,900 5,054,500 3,118,700
Incidence, any
Observed with screening 0.108 0.217 0.279 0.290 0.285 0.294 0.239 0.286
Expected without screening1 0.113 0.211 0.236 0.261 0.288 0.309 0.237 0.262
Excess relative risk (in %)1 -4 3 18* 11* -1 -5 1 9*
Incidence, localised at diagnosis
Observed with screening 0.054 0.119 0.168 0.182 0.182 0.181 0.143 0.177
Expected without screening1 0.045 0.095 0.128 0.131 0.158 0.173 0.116 0.141
Excess relative risk (in %)1 20* 26* 56* 39* 15* 5 23* 26*
Incidence, non-localised at diagnosis
Observed with screening 0.056 0.093 0.098 0.092 0.092 0.104 0.088 0.097
Expected without screening1 0.071 0.100 0.105 0.112 0.117 0.124 0.105 0.106
Excess relative risk (in %)1 -21* -7 -6 -18* -21* -16* -16* -9*
Mortality
Observed with screening 0.017 0.028 0.044 0.048 0.056 0.067 0.041 0.052
Expected1 without screening 0.012 0.022 0.035 0.046 0.057 0.064 0.037 0.051
Excess relative risk1 (in %) 42* 29* 24 5 -2 4 10 3
1 (Observed – expected)/expected * Significant at 0.05 levelBMC Public Health 2008, 8:38 http://www.biomedcentral.com/1471-2458/8/38
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municipalities might have got a three-year invitational
interval instead of the recommended two-years for few
birth cohorts. Sometimes the first screen could take place
at age 51. All these affect obtaining less than full 100%
age-specific coverage. After all, these deficits in screening
coverage had only a minor impact in the national pro-
gramme.
When considering ages targeted for screening, one limita-
tion was that the screening coverage was not complete in
ages 60–69. Another limitation was that there had been
during the late 1990s another population-based invita-
tional screening modality than the organised programme
in several municipalities in this age group, paid by the
women themselves. There is not much information avail-
able on the functioning of the self-paid modality. Accord-
ing to the only published information on a nation-wide
basis, invitational coverage of this modality in ages 60–69
could have been almost at the same level as of organised
screening modality during late 1990s [19]. Based data
from Turku city, attendance rates in the self-paid modality
could have been about 20% lower among women in age
60 to 69 than in the organised screening modality that is
paid by the municipalities [20].
In the randomised screening trials an average effect of
about -25% has been reported in the refined mortality rate
among invited, when the screening programme has been
run in ages 50–69 [1]. The current study indicated an aver-
age effect of -11.1% in the population-based refined mor-
tality rates by respective age groups. Effects associated
with screening taking place in ages 50–59 years, as prima-
rily defined in the Finnish screening policy, have not been
reported in detail from the randomised studies. In the
Swedish trials, the screening effect was -16% (95% CI
from -30% to 1%) among women started screening in age
50–59 and -33% (95% CI from -47% to -16%) among
women started screening in age 60–69, respectively [21].
Unlike in the Finnish programme, those women who had
started screening at age 50–59 were systematically
screened also when they reached age 60 or more; therefore
our current estimate (-8.6%) is not directly comparable.
Among women aged 60–69 at diagnosis the effect from
the current study was -16.6%, only about half of the
impact reported from the above randomised studies. Con-
cerning the latter comparison, it is likely that the deficit in
the actual screening coverage in that age affects the Finn-
ish rates.
A larger point estimate in effectiveness for screening
women at age 50–69, in comparison with screening
women only at age 50–59, is supported also by a recent
report from the Copenhagen BC screening programme,
analysis based on age at death (not age at screen as in our
study) [3]. The average effect on the refined mortality in
ages 50 to 79 at death was -25%; the corresponding aver-
age estimate at age 50 to 64 at death (where screening in
age 50–59 should have primarily affected) as extracted
from the report is -11% and at ages 65–79 at death (where
screening in age 60–69 should have primarily affected) -
30%. Our results on the refined mortality are in line with
the findings from Copenhagen for the younger targeted
age group, not with the findings for the older targeted age
group.
An earlier study has attempted to estimate how big impact
would have taken place in the 'routine' breast cancer
deaths in Finland, if a biannual breast cancer screening
programme was started in 1988 among women in ages 50
to 69 [22]. Screening coverage of 80% was assumed, as
well as efficacy as reported from randomised trials. In ages
50 to 69 at death, the estimated average decrease in the
Table 3: Excess relative risks of incidence of and mortality from breast cancer in 1992–2002, and of incidence-based mortality in 
1992–2002 in comparison with the baseline without screening by age. The baseline without screening was estimated by models using 
information from time before screening and in age groups not subjected for service screening (40–49; and 65–69 up to the year 1991, 
see the text).
Excess relative 
risk (%) by age 
group (years) A
50–54 55–59 60–64 65–69 50–59 60–69 50–69
Incidence 19.1(12.0,26.5) 11.5(4.3,19,3) 2.0(-5.0,9.4) -2.2(-8.7,4.8) 15.9(9.9,22.3) 1.1(-4.7,7.3) 8.0(2.9,13.4)
Loc incidence 40.9(29.2,53.6) 31.8(19.3,45.6) 10.6(-0.5,22.8) 2.8(-7.5,14.3) 37.8(27.5,48.8) 8.6(-0.8,18.8) 22.5(14.2, 31.3)
Non-loc. 
incidence
2.5(-5.9,11.7) -13.0(-20.5,-4.8) -17.8(-25.2,-9.6) -15.2(-23.6,-5.9) -4.8(-11.2,2.1) -15.8(-22.4,-8.7) -9.0(-14.6,-3.2)
Mortality 1.9(-10.2,15.7) -10.8(-22.1,2.3) -10.9(-21.9, 1.7) -12.1(-23.0,0.4) -3.5(-13.6,7.9) -9.2(-18.8,1.6) -5.6(-14.4,4.0)
Incidence-based 
mortality
-3.1(-14.5,9.9) -14.7(-24.8,-2.0) -17.1 (-28.0,-4.7) NA -8.6(-17.8,1.7) -16.6(-25.0,-4.2) B -11.1(-19.4,-2.1) C
A Age at diagnosis was used for the estimates for BC incidence and incidence-based mortality; age at death was used for the BC mortality.
B Includes ages 60–64 at diagnosis. Excess relative risk is not available for age group 65–69 since for them the steady state started in 1997.
C Includes ages 50–64 at diagnosis.BMC Public Health 2008, 8:38 http://www.biomedcentral.com/1471-2458/8/38
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population-based routine death rate from breast cancer
was -8% during the first five years since the onset of the
programme; and -14% and -19% during the next five-year
periods. The estimate of the current study (-5.6%) was
clearly smaller than the two latter estimates. It is likely
that these findings of small impacts on the population-
based rates in the current study can be explained largely by
the rather narrow age group targeted historically in our
country.
Impacts of breast cancer screening on incidence have not
been investigated adequately for the service screening pro-
grammes. In randomised trials, controls usually became
screened at the end of randomisation period (usually
within 6–8 years since the onset) and therefore follow-up
of incidence is affected by screening [1]. There is a unique
report from a trial in Malmö, Sweden, where controls in
ages 55–69 were not invited; suggesting about 10% excess
in lifetime BC incidence attributable to screening [23].
There is another study, using a non-randomised design,
suggesting much bigger excess incidence rates [24]. A
long-term follow-up study of a recent routine screening
programme and with correction for lead-time has sug-
gested, however, that only rather small over-diagnosis of
some 5% in relative terms might be expected [25]. A
recent trend study from Finland, including a very long fol-
low-up time since the last screen when screening was
done in ages 50–59, reported no excess in the estimated
cumulative incidence [26]. The current study suggests that
if there is over-diagnosis in the Finnish BC screening pro-
gramme, the relative estimate is small. Even a small excess
risk in the breast cancer incidence may mean considerable
numbers when contrasted with the numbers of deaths
prevented; particularly when taking into account that the
number of deaths prevented by screening in ages 50 to 59
only is rather small.
There was a consistent decrease in BC mortality since the
mid-1990s in all the age groups studied. It was important
to note also among women before age targeted for screen-
ing. This development may indicate an effect from
improved treatments or from improved early diagnoses
(stage migration) also outside organised screening. This
trend was in a general agreement with the finding from US
that developments in treatment and in early diagnosis in
other fields of health care than in organised screening
probably affect more in rather young age groups, say, 40
to 54, than in the older targeted ages of screening pro-
grammes [27]. This development could affect the num-
bers of deaths prevented and also the relative screening
effect in the future.
One further limitation in estimating the tentative screen-
ing impact was that women in ages 40–49 (almost
entirely unscreened), as well as women in ages 65–69 dur-
ing the first few years of the programme, contributed to
expectation without screening. We thought that inclusion
of non-screened age groups was necessary to estimate
screening effects (Table 3), because there were no
unscreened regions in the country and otherwise we could
not get an idea of developments during screening period
– such as changes in background risk, changes in diagnos-
tic activity or use of mammograms outside screening; or
improvements in treatment – in absence of screening. For
estimating the steady phase of the programme, when the
prevalence screens take place mainly at age 50, we consid-
ered that the very low coverage of screening invitations
below age 50 does not affect materially. Including experi-
ence in unscreened age groups during screening period
seemed to alter the estimates meaningfully, compare the
results obtained in the Tables 1 and 2 to those in the Table
3.
Irrespective of the decreasing trend since the mid-1990s,
there was a rather large overall increase in the mortality
rates in the long-term trend among women at age below
50 years. The increase in the background risk has been ear-
lier reported to be among the highest in Finland [28] and
it is the most likely explanation. Among young women
the relative risk estimates may be imprecise, due to small
numbers. One problem for the modelling was also that
the baseline absolute mortality rate was much lower
among the youngest age groups than among women in
screening ages (Tables 1 and 2).
The incidence and mortality were modelled with the Pois-
son regression with numerical calendar time and polyno-
mial functions of 5-year age group and synthetic cohort.
When the orders of polynomials of age and cohort are
included in the model, the changes in the incidence and
mortality rates with age and cohort can be taken ade-
quately into account. One must, however, remember care-
fully to check the sensibility and sensitivity of the model-
based rates since this kind of modelling can lead to incred-
ible predictions. We are looking forward to compare the
current modelling results with other approaches for esti-
mating incidence and mortality, especially using inci-
dence-based mortality.
The effect of screening on incidence and mortality can be
considered stable after 5 years since the beginning of the
screening. Therefore the first five years with various effects
on incidence and mortality were excluded from the basic
descriptive analyses. One further problem when consider-
ing the national trends was that the Finnish programme
was implemented gradually due to the randomised design
during the implementation phase. Including or excluding
that period did not materially affect the estimates.BMC Public Health 2008, 8:38 http://www.biomedcentral.com/1471-2458/8/38
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In this study, information on screening was based mainly
on the dynamic (open) information on the whole tar-
geted population in ages 50–59. In older ages, 60–69
years, women were invited only partially or irregularly.
Expected rates without screening were based on the pat-
terns in time before the national screening programme, as
well as on the experiences of non-screened age groups
during screening era. As the whole population in the
mainly targeted age was invited, there was no experience
among non-screened in that age during the screening
period. Using individual-level information on invited and
screened during the current screening periods could still
bring new information for evaluating screening effective-
ness.
Conclusion
In conclusion, the current study demonstrates that BC
screening in Finland has been effective in reducing mor-
tality from breast cancers. The impact is smaller than that
observed in randomised trials. This may be explained at
least partially by the rather narrow age group targeted; a
great part of women in ages 60–69 that were included in
the targeted populations in the randomised screening tri-
als for breast cancer, were unscreened in our country. The
results warrant considering whether screening should be
targeted up to age 69. Considering rather small relative
estimates, further research using individual-level informa-
tion on the invited and screened can bring new informa-
tion on the effectiveness of the screening programme.
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